Pre-market hot trades in US stocks: Satellogic signs agreement with Portugal, stock price rises 7.20% in pre-market, market optimistic about the growth of space technology demand

Pre-market Hot Trades in US Stocks Satellogic is up 7.20% in pre-market trading. Based on recent key news: On January 13, Satellogic signed a $18 million agreement with Portugal to deliver two high-resolution satellites. This agreement aims to enhance Portugal's Earth observation capabilities and promote its applications in civil, environmental, and security missions. This news drove Satellogic's stock price up 15%, reaching $3.48. On January 12, Satellogic announced an agreement with CEiiA in Portugal to provide two NewSat Mark V satellites. This move supports European defense and space programs, further enhancing Portugal's national space capabilities. On January 11, Satellogic's long-term analysis shows its fundamental data-driven growth potential, despite not considering the latest price-sensitive company announcements, the market remains optimistic about its future performance. Industry trends are positive, with growing demand for space technology. Top Gainers in Pre-market US Stocks Ambitions Enterprise is up 131.44% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. AlphaTON Capital is up 126.37% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. Beyond Air is up 78.09% in pre-market trading. Based on recent key news: On January 13, Beyond Air's NeuroNOS subsidiary was acquired for 85% of its shares by XTL Biopharmaceuticals, and Beyond Air will receive up to $32.5 million in milestone payments. This news drove Beyond Air's stock price up 78.09% in pre-market trading, with a significant increase in trading volume. On January 13, Beyond Air's NeuroNOS received FDA orphan drug designation for the treatment of Phelan-McDermid syndrome and glioblastoma. This development enhances market confidence in the company's R&D capabilities, further driving the stock price up. On January 13, XTL Biopharmaceuticals' stock price rose 15.87%, related to increased trading activity with Beyond Air, indicating positive market sentiment towards the biopharmaceutical industry. The biopharmaceutical sector has been active recently, with significant capital inflow